156 results on '"Asraf, Keren"'
Search Results
2. Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
3. Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up
4. Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose
5. Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
6. Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy
7. Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines
8. Corrigendum to 'Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up', Clinical Microbiology and Infection Volume 29, Issue 7, July 2023, Pages 918-923
9. Low FXIII activity levels in intensive care unit hospitalized COVID-19 patients
10. Risk factors and correlates of protection against XBB SARS-CoV-2 infection among health care workers
11. Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
12. Corrigendum to “Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up” [Clin Microbiol Infect] 29 (7) (2023) 918–923
13. Humoral Immunity of Unvaccinated COVID-19 Recovered vs. Naïve BNT162b2 Vaccinated Individuals: A Prospective Longitudinal Study
14. Intranasal telmisartan ameliorates brain pathology in five familial Alzheimer’s disease mice
15. Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel
16. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study
17. Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
18. High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
19. Humoral Response to the Fourth BNT162b2 Vaccination and Link Between the Fourth Dose, Omicron Infection, and Disease Severity in Renal Transplant Recipients
20. Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
21. Angiotensin Converting Enzyme Inhibitors Ameliorate Brain Inflammation Associated with Microglial Activation: Possible Implications for Alzheimer’s Disease
22. Maternal and Neonatal Immune Responses Following COVID-19 Infection and Vaccinations in Pregnancy
23. Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years
24. The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
25. Association between Thrombin Generation and Clinical Characteristics in COVID-19 Patients
26. Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022
27. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection
28. Candesartan ameliorates brain inflammation associated with Alzheimerʼs disease
29. Early Adverse Events and Immune Response Following Second and Third COVID-19 Vaccination in Pregnancy
30. Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-up
31. Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
32. Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients
33. Association between Thrombin Generation and Clinical Characteristics in COVID-19 Patients.
34. Durability of the immune response to a third BNT162b2 dose; five months follow-up
35. The Predictive Value of Serum ACE2 and TMPRSS2 Concentrations in Patients with COVID-19—A Prospective Pilot Study
36. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
37. miR-155: A Potential Biomarker for Predicting Mortality in COVID-19 Patients
38. 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC
39. Correlates of Protection of BNT162b2 Against COVID-19 Infection and Intensity of Symptomatic Disease; the Israeli COVID-19 Family Study (ICoFS)
40. Superior immunogenicity and effectiveness of the 3rd BNT162b2 vaccine dose
41. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
42. Differential effect of intranasally administrated kinin B1 and B2 receptor antagonists in Alzheimerʼs disease mice
43. Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience
44. Presence of SARS-CoV-2 antibodies in lactating women and their infants following BNT162b2 messenger RNA vaccine
45. Differential regulation of astrocyte prostaglandin response by kinins: Possible role for mitogen activated protein kinases
46. Humoral Response to the Fourth BNT162b2 Vaccination and Link Between the Fourth Dose, Omicron Infection, and Disease Severity in Renal Transplant Recipients
47. Potential antigenic cross-reactivity between SARS-CoV-2 and Dengue viruses
48. The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
49. Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience.
50. Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.